PL4041733T3 - Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające - Google Patents
Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierająceInfo
- Publication number
- PL4041733T3 PL4041733T3 PL20887669.8T PL20887669T PL4041733T3 PL 4041733 T3 PL4041733 T3 PL 4041733T3 PL 20887669 T PL20887669 T PL 20887669T PL 4041733 T3 PL4041733 T3 PL 4041733T3
- Authority
- PL
- Poland
- Prior art keywords
- mountry
- dihydrobenzofuran
- indene
- dihydro
- derivatives
- Prior art date
Links
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146679 | 2019-11-15 | ||
| PCT/KR2020/015864 WO2021096238A1 (en) | 2019-11-15 | 2020-11-12 | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4041733T3 true PL4041733T3 (pl) | 2024-09-23 |
Family
ID=75911374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20887669.8T PL4041733T3 (pl) | 2019-11-15 | 2020-11-12 | Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12522602B2 (pl) |
| EP (2) | EP4389744B1 (pl) |
| JP (2) | JP7671751B2 (pl) |
| KR (1) | KR20210059632A (pl) |
| CN (2) | CN114829361B (pl) |
| AU (1) | AU2020384066B2 (pl) |
| BR (1) | BR112022009409A2 (pl) |
| CA (1) | CA3154313A1 (pl) |
| ES (2) | ES3058346T3 (pl) |
| MX (1) | MX2022005679A (pl) |
| PL (1) | PL4041733T3 (pl) |
| RS (1) | RS65662B1 (pl) |
| WO (1) | WO2021096238A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| IL306116A (en) * | 2021-05-11 | 2023-11-01 | Yuhan Corp | New compounds with inhibitory activity against glucosylceramide synthase or an acceptable pharmaceutical salt thereof, processes for their preparation and pharmaceutical preparations containing them |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| CA3268132A1 (en) * | 2022-10-24 | 2024-05-02 | Yuhan Corporation | NEW DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE SALT AND ITS PREPARATION PROCESSES |
| JP2025534728A (ja) * | 2022-10-24 | 2025-10-17 | ユーハン・コーポレイション | ジメチル－２，３－ジヒドロ－１ｈ－インデン誘導体の改良された製造方法 |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| KR20250117295A (ko) * | 2024-01-26 | 2025-08-04 | 주식회사유한양행 | 고셔병의 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| US8003617B2 (en) | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| US8030081B2 (en) | 2007-02-28 | 2011-10-04 | Denka Seiken Co., Ltd. | Reagent for quantitative determination of small, dense LDLs |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| WO2010091104A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| AU2012231275A1 (en) | 2011-03-18 | 2013-10-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| WO2013059119A1 (en) * | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| CN105745206B (zh) * | 2013-09-20 | 2019-08-13 | 生物马林药物股份有限公司 | 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂 |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
| US20200308168A1 (en) * | 2017-12-04 | 2020-10-01 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2 |
-
2020
- 2020-11-12 PL PL20887669.8T patent/PL4041733T3/pl unknown
- 2020-11-12 ES ES24163536T patent/ES3058346T3/es active Active
- 2020-11-12 EP EP24163536.6A patent/EP4389744B1/en active Active
- 2020-11-12 KR KR1020200150785A patent/KR20210059632A/ko active Pending
- 2020-11-12 BR BR112022009409A patent/BR112022009409A2/pt unknown
- 2020-11-12 MX MX2022005679A patent/MX2022005679A/es unknown
- 2020-11-12 US US17/755,843 patent/US12522602B2/en active Active
- 2020-11-12 CA CA3154313A patent/CA3154313A1/en active Pending
- 2020-11-12 ES ES20887669T patent/ES2984255T3/es active Active
- 2020-11-12 JP JP2022527911A patent/JP7671751B2/ja active Active
- 2020-11-12 CN CN202080075084.9A patent/CN114829361B/zh active Active
- 2020-11-12 AU AU2020384066A patent/AU2020384066B2/en active Active
- 2020-11-12 RS RS20240700A patent/RS65662B1/sr unknown
- 2020-11-12 CN CN202410840972.5A patent/CN118955495A/zh active Pending
- 2020-11-12 EP EP20887669.8A patent/EP4041733B1/en active Active
- 2020-11-12 WO PCT/KR2020/015864 patent/WO2021096238A1/en not_active Ceased
-
2025
- 2025-04-21 JP JP2025069586A patent/JP2025111591A/ja active Pending
- 2025-12-12 US US19/418,159 patent/US20260098038A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041733C0 (en) | 2024-05-08 |
| EP4041733A4 (en) | 2023-08-30 |
| AU2020384066B2 (en) | 2025-10-30 |
| JP2025111591A (ja) | 2025-07-30 |
| BR112022009409A2 (pt) | 2022-08-09 |
| ES2984255T3 (es) | 2024-10-29 |
| EP4389744C0 (en) | 2025-12-03 |
| CN118955495A (zh) | 2024-11-15 |
| JP7671751B2 (ja) | 2025-05-02 |
| RS65662B1 (sr) | 2024-07-31 |
| CA3154313A1 (en) | 2021-05-20 |
| MX2022005679A (es) | 2022-06-27 |
| AU2020384066A1 (en) | 2022-04-21 |
| ES3058346T3 (es) | 2026-03-10 |
| EP4389744A1 (en) | 2024-06-26 |
| EP4041733A1 (en) | 2022-08-17 |
| JP2023503830A (ja) | 2023-02-01 |
| WO2021096238A1 (en) | 2021-05-20 |
| CN114829361B (zh) | 2024-07-16 |
| US12522602B2 (en) | 2026-01-13 |
| US20230002379A1 (en) | 2023-01-05 |
| EP4389744B1 (en) | 2025-12-03 |
| KR20210059632A (ko) | 2021-05-25 |
| CN114829361A (zh) | 2022-07-29 |
| US20260098038A1 (en) | 2026-04-09 |
| EP4041733B1 (en) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4041733T3 (pl) | Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| GEAP202115066A (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| CY1119357T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα | |
| IL285739B2 (en) | Crystalline Form A of Hydrochloride Salt of (S)-(4,5-DIHYDRO-7H-THIENO[3,2c]PYRAN-7YL)-N-METHYLMETHANAMINE HCL and Related Pharmaceutical Preparations | |
| HRP20240643T1 (hr) | Heterociklički spojevi za inhibiciju aktivnosti tyk2 | |
| DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
| BR112017020081A2 (pt) | análogos deuterados de etifoxina, seus derivados e usos dos mesmos | |
| EP4221690A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP4041734C0 (en) | DERIVATIVES HAVING A 1,2,3,4-TETRAHYDRONAPHTHALENE FRACTION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
| MX2017013678A (es) | Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende. | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| EP4135699A4 (en) | Pharmaceutical compositions | |
| EP3914362C0 (en) | Exercise machine | |
| JOP20170197A1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| MX383577B (es) | Derivados sustituidos de guanidina. | |
| CO2020011860A2 (es) | Compuestos de 4–metildihidropirimidinona y su uso farmacéutico | |
| BR112022007207A2 (pt) | Composição farmacêutica que compreende selexipag | |
| SA521421354B1 (ar) | مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون | |
| EP3917926C0 (en) | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, THEIR USES | |
| KR102474935B9 (ko) | 파에오놀 및 판테놀 또는 이들의 약학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물 | |
| PL3746441T3 (pl) | Związek farmaceutyczny, jego sole, jego preparaty oraz sposoby ich wytwarzania i zastosowania | |
| ZA202101652B (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| KR102182651B9 (ko) | 4--N--1H-피라졸로[3,4-b]피리딘-3-일)벤즈아미드 유도체, 또는 이의 약학적으로 허용 가능한 염의 미백용 소재 용도 | |
| KR102256804B9 (ko) | N-페닐-2-티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물 |